Board revised utilisation of preferential-issue proceeds to Rs 58.7 Cr versus Rs 99.0 Cr estimated earlier, after only 4,64,410 of 21,10,000 equity shares were allotted; 19,30,000 warrants were fully subscribed. Working capital allocation retained at Rs 35 Cr, while debt repayment was reduced to Rs 10 Cr. Plant and machinery and marketing allocations were deferred, with Rs 13.7 Cr assigned to general corporate purposes. This is the company's first equity-linked capital raise after a prolonged self-funded period and shifts funding toward operating liquidity. Reduced proceeds limit deleveraging and defer capacity expansion; the remaining Rs 35.5 Cr from warrant conversion is contingent on exercise, with any lapse requiring a further utilisation revision. Issue dilution and funding execution remain key risks.
No events have occurred recently